Company profile: True North Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology therapeutics that selectively inhibit the Complement pathway for diseases of high unmet clinical need, featuring lead monoclonal antibody TNT009 targeting the Classical Complement pathway to selectively inhibit downstream phagocytosis, inflammation, and cell lysis.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to True North Therapeutics
Amryt Pharma
HQ: Ireland
Website
- Description: Provider of specialty pharmaceuticals for rare and orphan diseases: Myalept/Myalepta (metreleptin) for leptin deficiency complications in generalized or partial lipodystrophy; Mycapssa (octreotide capsules) for long-term maintenance therapy in acromegaly; Juxtapid/Lojuxta (lomitapide) for adults with HoFH; Filsuvez (Oleogel-S10) for partial-thickness wounds in junctional and dystrophic EB; and AP103, a pre-clinical gene therapy for DEB.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amryt Pharma company profile →
Synageva BioPharma
HQ: United States
Website
- Description: Provider of novel, next generation and follow on protein therapeutics developed and commercialized using the proprietary Synageva Expression Platform (SEPTM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synageva BioPharma company profile →
Acer Therapeutics
HQ: United States
Website
- Description: Provider of therapies for serious rare diseases, focused on acquiring, developing, and commercializing treatments. Portfolio includes OLPRUVA (U.S.-approved for urea cycle disorders) and investigational EDSIVO (vascular Ehlers-Danlos, COL3A1-positive), ACER-001 (Maple Syrup Urine Disease and other metabolic disorders), ACER-801 (vasomotor symptoms, PTSD), and ACER-2820 (host-directed therapy against viruses, incl. COVID-19).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acer Therapeutics company profile →
Glycomine
HQ: United States
Website
- Description: Provider of replacement therapies for rare diseases, including GLM101, a mannose-1-phosphate replacement therapy in clinical development for PMM2-CDG that delivers mannose-1-phosphate directly into cells to bypass PMM2 enzyme deficiency, and a Natural History Study, a longitudinal study to understand PMM2-CDG symptoms, progression, and clinical measures and biomarkers for the disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycomine company profile →
Imegen
HQ: Spain
Website
- Description: Provider of biomedical services and products for genetic analysis, offering diagnostic, prognostic, and preventive genetic services to improve health and quality of life, with the aim of being a worldwide reference in human genetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imegen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for True North Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to True North Therapeutics
2.2 - Growth funds investing in similar companies to True North Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for True North Therapeutics
4.2 - Public trading comparable groups for True North Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →